Development
Taysha Gene Therapies, Inc.
TSHA
$2.84
-$0.04-1.39%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -33.29% | 33.07% | 30.52% | 4.51% | -13.24% |
| Total Depreciation and Amortization | 34.35% | 44.82% | 72.92% | 138.62% | 252.60% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 533.62% | 111.90% | 105.19% | 108.20% | -2.80% |
| Change in Net Operating Assets | 284.20% | 13.91% | -64.27% | -38.27% | -138.76% |
| Cash from Operations | 70.27% | 63.49% | 49.93% | 24.11% | -48.36% |
| Capital Expenditure | 76.82% | 70.85% | 30.63% | -34.73% | -275.16% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 21.09% | 73.48% | 85.83% | 31.02% | 62.50% |
| Cash from Investing | 68.75% | 71.17% | 46.36% | -15.66% | -62.85% |
| Total Debt Issued | -- | -- | -- | -- | -66.71% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,429.01% | 252.43% | 19,155.60% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | 94.80% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 69.66% | 72.42% | 20.43% | -10.41% | -140.76% |
| Cash from Financing | 812.91% | -16.94% | 34.11% | 34.41% | -29.92% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 184.14% | 83.54% | 74.34% | 38.48% | -77.10% |